N/A N=156 Typing of Human Papilloma Virus (HPV) From Female Genital Warts
Genital Warts · Human Papilloma Virus
Primary: HPV DNA and HIV Status — 96; 19; 4; 5 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=108 Topical NVN1000 for the Treatment of External Genital and Perianal Warts
Genital Warts · Perianal Warts
Primary: Efficacy: Complete Clearance of Baseline External Genital and Perianal Warts at or Before Week 12 — 2; 5; 2; 10 Participants
Phase 3 N=511 Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts
Genital Warts
Primary: Proportion of Subjects Achieving Complete Clearance of All Warts (Baseline and New) at the End of Study. — 0.248; 0.294; 0.09 proportion of participants
N/A N=150 Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population
Condylomata Acuminata
Primary: Human Papillomavirus (HPV) Types in External Genital Warts (EGW) — 80; 12.66; 0.66; 2 percentage of participants
Phase 3 N=470 Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts
Genital Warts
Primary: Proportion of Subjects With Complete Clearance of All Warts (Both Presented at Baseline and Newly Emerged Warts) at End of Study — 0.191; 0.272; 0.103 participants
Phase 2 N=70 Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream
Anus Neoplasms
Primary: Final Response of Anal High-grade Squamous Intraepithelial Lesions (HSIL) — 3; 0; 7; 3 participants — p=.042
N/A N=32 The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata
HIV Positive · Anal Condylomata · Anal Warts
Primary: The Primary Endpoint of This Study is Persistence and Recurrence of Anal Warts as Compared Between the Experimental and Control Groups. — 1; 1 participants
Phase 2 N=2 Intralesional HPV Vaccine for Condylomata
Human Papilloma Virus · Warts · Warts, Genital
Primary: Change in Wart Number — 0.5 warts
Phase 2 N=33 Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus
Anal Cancer · Precancerous Condition
Primary: Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL) — 0.515 proportion of participants
N/A N=127 The Human Papilloma Virus Effect on Sexual Life
Human Papillomavirus Infection
Primary: Female Sexual Function Index (FSFI) Score — 0.8; 1.2; 0.9; 0.7 score on a scale
Phase 3 N=52 Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts
Genital Warts
Primary: Change in the Maximum Size of the Genital Wart Lesion Over the Trial Period (as Measured in mm) — 8; 6; 11; 7 Participants
Phase 3 N=91 Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions
Anal Intraepithelial Neoplasia · High-grade Squamous Intraepithelial Lesion · HIV Infection
Primary: Percentage of Participants Achieving Complete Response in 5-FU Arm and Observation Arm Using ITT Population — 5; 9 Participants — p=0.1877
Phase 2 N=23 VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2
Anal Neoplasm
Primary: Percentage of Participants With no Histologic Evidence of Anal or Anal/Peri-Anal HSIL and no Evidence of HPV-16/18 at Week 36 — 9.1 percentage of participants — p=0.8633
N/A N=42 Treatment of External Genital Warts With Cryotherapy and Sinecatechins 15% Ointment
External Genital Warts
Primary: Number of Participants With Complete Clearance, — 0; 0; 3; 5 participants
N/A N=200 Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With Men
Human Papillomavirus
Primary: HPV Prevalence — 61 participants
Phase 3 N=575 Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women
HIV Infections
Primary: Time to the First New Persistent Infection of HPV 6, 11, 16, or 18 — 1.90; 1.04; 2.92; 2.05 Years — p=0.350
Phase 2 N=44 VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions
Anal Intraepithelial Neoplasia · High Grade Squamous Intraepithelial Neoplasia · HIV Positivity
Primary: Overall Response Rate at 48 Weeks — 10 Participants
N/A N=20 Development of a Health-Related Symptom Index for Participants With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions
High Grade Anal Canal Squamous Intraepithelial Neoplasia · Human Immunodeficiency Virus
Primary: Development of Spanish-language Version of the Anal Cancer/High-grade Squamous Intraepithelial Lesions (HSIL) Outcomes Research (ANCHOR) Health-related Quality of Life…
Early Phase 1 N=13 Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia
Cervical Intraepithelial Neoplasia Grade 2/3 · Cervical Squamous Cell Carcinoma In Situ · Cervical Squamous Intraepithelial Neoplasia 2
Primary: Feasibility of Intravaginal Use 5-FU and Imiquimod on Alternating Weeks in Women With Biopsy Confirmed High Grade Cervical Squamous Intraepithelial Lesions. — 4; 1…
Phase 2 N=133 Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)
Cervical Intraepithelial Neoplasia · Cervical Dysplasia
Primary: Incidence of Objective Response — 32; 36; 30; 0 Participants — p=0.043
Phase 2 N=88 Efficacy and Tolerability of Topical LFX453 for External Genital Warts
External Genital Warts
Primary: Complete Clearance of Disease at Week 14 — 1; 0; 0; 0 participants — p=0.862
N/A N=46 Anal Human Papillomavirus in Inflammatory Bowel Disease Study
Inflammatory Bowel Disease (IBD) · Ulcerative Colitis (UC) · Crohn's Disease (CD)
Primary: Number of Participants With Anal HPV of Any Type, Single Type, and Multiple Types — 41; 16; 25 participants
Phase 2 N=59 Treatment of Oral Warts in HIV+ Patients
Papillomatosis · HIV Infections
Primary: Change in Total Oral Mucosal Area Covered by Warts. — 11; 2 participants — p=0.30
Phase 2 N=105 A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts
Condylomata Acuminata · Papillomavirus Infections · Skin Diseases, Viral
Primary: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts at the Study Day 84 (End of Treatment) Visit. — 11; 1; 9; 0 Participants — p=0.0048
Phase 3 N=466 Comparison Between Podofilox Topical Gel 0.5% and Allergan's Condylox® Gel 0.5% for External Anogenital Warts
External Anogenital Warts
Primary: Number and Percentage of Subjects With Total Disappearance of All Warts Within All Treated Areas. — 100; 102; 12 Participants
Phase 3 N=4,446 Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
Anal Cancer · High-grade Squamous Intraepithelial Lesion · HIV Infection
Primary: Anal Cancer Incidence — 173; 402 cases per 100,000 person years
N/A N=276 Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Anal Cancer · HIV Infection · Human Papilloma Virus Infection
Primary: Specificity of Each Other Methods of HSIL Detection for APTIMA Assay — 116 Participants
Phase 3 N=5,759 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
Cervical Cancer · Genital Warts
Primary: Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN)(Any Grade), Adenocarcinoma In Situ (AIS) or Cervical Cancer — 0; 1.2 incidence rate per 100…
N/A N=467 HPV Test-and-Treat-Strategy Versus Cytology-based Strategy for Prevention of CIN2+ in HIV-Infected Women
HIV-1 Infection
Primary: Cumulative Rate of Cervical Intraepithelial Neoplasia (CIN2+) (CIN2, CIN3 or Invasive Cancer) by Week 130 — 24.9; 26.5 Events per 100 persons
Phase 4 N=372 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study
Human Papillomavirus Infection
Primary: HPV Incidence Rates, Expressed as Incident Infections/1000 Infection-months at Risk. These Were Calculated Separately for Females and Males Across the Four Vaccine…